Senators urge CMS to delay biosimilar reimbursement policy

Sens. Pat Roberts (R-Kan.) and Tom Carper (D-Del.) led a bipartisan group of 20 U.S. senators who sent a (see BioCentury Extra, July 10).

Biosimilar manufacturers and members of the U.S. House of Representatives have urged CMS to drop the proposal and provide biosimilars with unique HCPCS codes and unique payment rates. Sponsors who wish to price biosimilars differently from one another would prefer to have unique codes (see BioCentury Extra, Aug. 5) ...